Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese mice.

Authors: Poekes, Laurence  Legry, Vanessa  Schakman, Olivier  Detrembleur, Christine  Bol, Anne  Horsmans, Yves  Farrell, Geoffrey C  Leclercq, Isabelle A 
Citation: Poekes L, etal., Clin Sci (Lond). 2017 Feb 1;131(4):285-296. doi: 10.1042/CS20160469. Epub 2016 Nov 1.
Pubmed: (View Article at PubMed) PMID:27803297
DOI: Full-text: DOI:10.1042/CS20160469

Fatty liver diseases are complications of the metabolic syndrome associated with obesity, insulin resistance and low grade inflammation. Our aim was to uncover mechanisms contributing to hepatic complications in this setting. We used foz/foz mice prone to obesity, insulin resistance and progressive fibrosing non-alcoholic steatohepatitis (NASH). Foz/foz mice are hyperphagic but wild-type (WT)-matched calorie intake failed to protect against obesity, adipose inflammation and glucose intolerance. Obese foz/foz mice had similar physical activity level but reduced energy expenditure. Thermogenic adaptation to high-fat diet (HFD) or to cold exposure was severely impaired in foz/foz mice compared with HFD-fed WT littermates due to lower sympathetic tone in their brown adipose tissue (BAT). Intermittent cold exposure (ICE) restored BAT function and thereby improved glucose tolerance, decreased fat mass and liver steatosis. We conclude that failure of BAT adaptation drives the metabolic complications of obesity in foz/foz mice, including development of liver steatosis. Induction of endogenous BAT function had a significant therapeutic impact on obesity, glucose tolerance and liver complications and is a potential new avenue for therapy of non-alcoholic fatty liver disease (NAFLD).


Gene Ontology Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 13673804
Created: 2018-06-23
Species: All species
Last Modified: 2018-06-23
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.